Processing

Please wait...

Settings

Settings

1. CN107073016 - Celastrol and derivatives for the treatment of obesity

Office China
Application Number 201580027586.3
Application Date 26.03.2015
Publication Number 107073016
Publication Date 18.08.2017
Publication Kind A
IPC
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
56
Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
56
Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
58
containing heterocyclic rings, e.g. aldosterone, danazol, stanozolol, pancuronium, digitogenin
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
3
Drugs for disorders of the metabolism
04
Anorexiants; Antiobesity agents
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
3
Drugs for disorders of the metabolism
08
for glucose homeostasis
10
for hyperglycaemia, e.g. antidiabetics
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
J
STEROIDS
63
Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
A61K 31/56
A61K 31/58
A61P 3/04
A61P 3/10
C07J 63/00
CPC
A61K 31/56
A61K 31/58
C07J 63/008
A61K 31/19
A61K 31/194
A61K 31/198
Applicants CHILDRENS MEDICAL CENTER
Inventors MAZITSCHEK RALPH
OZCAN UMUT
Priority Data 61/970,839 26.03.2014 US
Title
(EN) Celastrol and derivatives for the treatment of obesity
(ZH) 用于治疗肥胖症的雷公藤红素和衍生物
Abstract
(EN)
Pentacyclic triterpene compounds are provided herein. Also provided are pharmaceutical formulations containing a therapeutically effective amount of one or more of the compounds, or pharmaceutically acceptable salts or prodrugs thereof, in combination with one or more pharmaceutically acceptable excipients. The pharmaceutical formulations can be administered to a pre-obese, obese, or morbidly obese patient to induce weight loss, reduce body fat, reduce food intake, improve glucose homeostasis, prevent obesity, or a combination thereof. The compounds can also be co-administered with leptin or a leptin analog.

(ZH)
本文中提供五环三萜化合物。还提供医药制剂,其含有治疗有效量的一或多种化合物或其医药学上可接受的盐或前药与一或多种药学上可接受的赋形剂的组合。可向超重、肥胖或病态肥胖患者投与所述医药制剂以引起体重减轻、降低体脂肪、减少食物摄入、改良葡萄糖稳态、预防肥胖症或其组合。化合物也可与瘦素或瘦素类似物共同投与。